The Global live attenuated vaccines Market size is projected to reach US$ 66.75 Bn at the end of the forecast period at a CAGR of 10.7%.Global live Attenuated Vaccines Market Dynamics:
The report comprises of worldwide Live Attenuated Vaccines Market presentation in terms of revenue from various segments and detailed evaluation of the trends and factors that are playing a substantial role in the market. These factors involve the drivers, restraints, opportunities and challenges for the key companies and stakeholders in the industry.To know about the Research Methodology :- Request Free Sample Report Growing Prevalence of infectious diseases and rising awareness regarding vaccination led to increasing demand for novel treatment. Furthermore, the Increasing occurrence of infectious diseases, characteristics of live attenuated vaccines such as oral direction, long-lasting, and high effectiveness propel the market Also, increasing investment by government and pharmaceutical companies and various initiatives taken by the government such as compulsory vaccines for children’s, polio campaigns which resulted to completely eradicate polio cases, are also, few factors forecasting the market growth and driving the demand for live attenuated vaccines globally. However, live attenuated vaccines also have some limitations. For instance, Regulatory hurdles, environmental risks and genetic stability. Moreover, because of limited access to refrigerators in a few countries, these vaccines can’t be used in those regions and likely to restrain the live attenuated vaccine market. The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.
Global live attenuated vaccines Market: Market Segment Analysis
Based on product type, the Tuberculosis is accounted for the largest market share in 2021 and is estimated to dominate during the forecast period. Tuberculosis is one of the major causes of death worldwide. While, BCG, (bacille Calmette-Guerin), is a vaccine used for the treatment of tuberculosis (TB), in countries with a high incidence of TB to prevent meningitis, childhood tuberculosis and miliary disease. Moreover, the effectiveness of the vaccine against adult pulmonary TB and the vaccine’s potential with tuberculin interference raises the demand for vaccine in the market. However, In July 2021, the Indian Council of Medical Research (ICMR) launched an anti-Tuberculosis vaccine, which is administered to six and above patients. Based on route of administration, the intramuscular injection is estimated to have the largest share and is projected to grow at xx% CAGR and likely to maintain its dominance during the forecast period. The maximum supply and sales of intramuscular injection globally led to generate large revenue. Intramuscular is associated with, maximizing the immunogenicity and minimizing the reactogenicity, for example, the immunogenicity of varicella and yellow fever is greater as compared to subcutaneous injection and gives good immune response when administered intramuscularly. Hence, simplifying the vaccination practice.Global live Attenuated Vaccines Market: Regional Insights
Geographically, North America was valued US$ xx Mn in 2021 and is expected to reach US$ xx Mn by 2027, growing with a CAGR of xx%, and is accounted to dominate the global live attenuated vaccines market because of the major preventive measures taken to increasing occurrence of infectious diseases and growing awareness towards vaccination. Additionally, different initiatives by the government and public awareness program for vaccination against diseases like measles, influenza, etc., enhance the market growth. The US contributes the major share and as per estimation, on 15 June 2021, from over-all 16 states in the U.S. In terms of vaccine inclusion, with the WHO guidelines it is estimated to have one of the prominent healthcare systems for preventive vaccine market globally and thus, is expected to propel the growth of the live attenuated vaccines market during the forecast period (2021-2029). The Asia Pacific is expected to have a major market share because of the high incidence rate of tuberculosis in the region. As per WHO, 60% of the world’s tuberculosis patients are from the Asia Pacific, mainly from emerging countries such as India, Pakistan, Indonesia, and China. Of which, India is accounted to have a large number of tuberculosis patients, The Middle East & Africa market is predicted to grow during the forecast period because to the increasing number of deaths from yellow fever and demand for live attenuated vaccines is high in the region. As per WHO, 32 countries in Africa are at optimum risk of yellow fever.Global live Attenuated Vaccines Market Competitive Landscape:
These market players in the Global live Attenuated Vaccines Market appears to be competitive because of existing large and small players. The key players implemented various strategies such as acquisition & collaborations, merges, Product launches and other crucial aspects contributing to growth and lessen the competition in the competitive landscape. Acquisition is the prominent strategy dominating the market accounting for up to 52% of share.Some of the Key Developments in the Market: Mergers & Acquisition -
• In July 2019, Coalition for Epidemic Preparedness Innovations (CEPI) and Valneva SE, a biotechnology company, proclaimed partnership to deliver up to US$ 23.4 Mn for manufacturing of vaccine and clinical development of VLA1553, which is, a vaccine for live-attenuated Chikungunya virus. • In September 2017, Merck has launched INNOVAX-ND-IBD, the first live vaccine that provides life-long protection against highly contagious diseases in poultry like, Marek’s disease (MD), Infectious Bursal Disease (IBD) and Newcastle Disease (ND). • In September 2019, Kenya merged with malawi and Ghana and launched the world’s first malaria vaccines. It is proceeding efficiently as malaria affect millions in Africa. •In may 2019, sanofi Pasteur was approved for the launch of its dengue fever vaccines DENGVAXIA in U.S by USFDA. The objective of the report is to present a comprehensive analysis of the Global live Attenuated Vaccines Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global live Attenuated Vaccines Market dynamics, structure by analyzing the market segments and projects the Global live Attenuated Vaccines Market size. Clear representation of competitive analysis of key players By Route of Administration, price, financial position, Product portfolio, growth strategies, and regional presence in the Global live Attenuated Vaccines Market make the report investor’s guideGlobal live Attenuated Vaccines Market Scope: Inquire before buying
Global live Attenuated Vaccines Market Report Coverage Details Base Year: 2021 Forecast Period: 2022-2029 Historical Data: 2017 to 2021 Market Size in 2021: US $ 29.59 Bn. Forecast Period 2022 to 2029 CAGR: 10.7% Market Size in 2029: US $ 66.75 Bn. Segments Covered: by Type • Viral Vaccine o Varicella (Chickenpox) Vaccine o Adenovirus Oral Vaccine (Military) o Oral Polio Vaccine (OPV) o Yellow Fever Vaccine o Vaccinia (Smallpox) Vaccine o Other Viral Vaccines • Bacterial Vaccine o BCG (Tuberculosis) Vaccine o Live Cholera Vaccine o Typhoid Oral Vaccine by Vaccine Development • Live Animals • Embryonated Eggs • Tissue Culture by Route of Administration • Intramuscular (IM) • Subcutaneous (SC) • Oral o intradermal (ID), o transcutaneous (TC), o nasal route • Other Routes by End-User • Clinics • Research Institute • Diagnostic Centers • Hospitals • Other End User Global live Attenuated Vaccines Market, by Region
• North America • Europe • Asia Pacific • Middle East and Africa • Latin AmericaGlobal live Attenuated Vaccines Market, key Players
• Merck & Co., Inc.* • GlaxoSmithKline plc • Pfizer Inc. • CSL Limited • MedImmune LLC • Sanofi • Astellas Pharma • Johnson and Johnson • Serum institute of India Pvt. Ltd. • Codagenix Inc. • BioDiem • AstraZeneca • Emergent BioSolutions Inc. • Vivaldi Biosciences Inc. • Daiichi Sankyo Co., Ltd. • Takeda Pharmaceutical Company Limited • NOVAVAX, INC. • Boehringer Ingelheim International GmbH • Sanaria Frequently Asked Questions: 1. Which region has the largest share in Global Live Attenuated Vaccines Market? Ans: North America region held the highest share in 2021. 2. What is the growth rate of Global Live Attenuated Vaccines Market? Ans: The Global Live Attenuated Vaccines Market is growing at a CAGR of 10.7% during forecasting period 2022-2029. 3. What is scope of the Global Live Attenuated Vaccines market report? Ans: Global Live Attenuated Vaccines Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Live Attenuated Vaccines market? Ans: The important key players in the Global Live Attenuated Vaccines Market are – Merck & Co., Inc.*, GlaxoSmithKline plc, Pfizer Inc., CSL Limited, MedImmune LLC, Sanofi, Astellas Pharma, Johnson and Johnson, Serum institute of India Pvt. Ltd., Codagenix Inc., BioDiem, AstraZeneca, Emergent BioSolutions Inc., Vivaldi Biosciences Inc., Daiichi Sankyo Co., Ltd., Takeda Pharmaceutical Company Limited, NOVAVAX, INC., Boehringer Ingelheim International GmbH, Sanaria 5. What is the study period of this market? Ans: The Global Live Attenuated Vaccines Market is studied from 2021 to 2029.
Global live Attenuated Vaccines Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global live Attenuated Vaccines Market Size, by Market Value (US$ Bn) & Volume (Unit) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global live Attenuated Vaccines Market Analysis and Forecast 6.1. Global live Attenuated Vaccines Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global live Attenuated Vaccines Market Analysis and Forecast, By Vaccine Development 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global live Attenuated Vaccines Market Value Share Analysis, By Vaccine Development 7.4. Global live Attenuated Vaccines Market Size (US$ Bn) Forecast, By Vaccine Development 7.5. Global live Attenuated Vaccines Market Analysis, By Vaccine Development 7.6. Global live Attenuated Vaccines Market Attractiveness Analysis, By Vaccine Development 8. Global live Attenuated Vaccines Market Analysis and Forecast, Route of Administration 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global live Attenuated Vaccines Market Value Share Analysis, Route of Administration 8.4. Global live Attenuated Vaccines Market Size (US$ Bn) Forecast, Route of Administration 8.5. Global live Attenuated Vaccines Market Analysis, Route of Administration 8.6. Global live Attenuated Vaccines Market Attractiveness Analysis, Route of Administration 9. Global live Attenuated Vaccines Market Analysis and Forecast, By Type 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global live Attenuated Vaccines Market Value Share Analysis, By Type 9.4. Global live Attenuated Vaccines Market Size (US$ Bn) Forecast, By Type 9.5. Global live Attenuated Vaccines Market Analysis, By Type 9.6. Global live Attenuated Vaccines Market Attractiveness Analysis, By Type 10. Global live Attenuated Vaccines Market Analysis and Forecast, By End user 10.1. Introduction and Definition 10.2. Key Findings 10.3. Global live Attenuated Vaccines Market Value Share Analysis, By End user 10.4. Global live Attenuated Vaccines Market Size (US$ Bn) Forecast, By End user 10.5. Global live Attenuated Vaccines Market Analysis, By End user 10.6. Global live Attenuated Vaccines Market Attractiveness Analysis, By End user 11. Global live Attenuated Vaccines Market Analysis, by Region 11.1. Global live Attenuated Vaccines Market Value Share Analysis, by Region 11.2. Global live Attenuated Vaccines Market Size (US$ Bn) Forecast, by Region 11.3. Global live Attenuated Vaccines Market Attractiveness Analysis, by Region 12. North America Live Attenuated Vaccines Market Analysis 12.1. Key Findings 12.2. North America Live Attenuated Vaccines Market Overview 12.3. North America Live Attenuated Vaccines Market Value Share Analysis, By Vaccine Development 12.4. North America Live Attenuated Vaccines Market Forecast, By Vaccine Development 12.4.1. Live Animals 12.4.2. Embryonated Eggs 12.4.3. Tissue Culture 12.5. North America Live Attenuated Vaccines Market Value Share Analysis, Route of Administration 12.6. North America Live Attenuated Vaccines Market Forecast, Route of Administration 12.6.1. Intramuscular (IM) 12.6.2. Subcutaneous (SC) 12.6.3. Oral 12.6.3.1. intradermal (ID), 12.6.3.2. transcutaneous (TC), 12.6.3.3. nasal route 12.6.4. Other Routes 12.7. North America Live Attenuated Vaccines Market Value Share Analysis, By Type 12.8. North America Live Attenuated Vaccines Market Forecast, By Type 12.8.1. Viral Vaccine 12.8.1.1. Varicella (Chickenpox) Vaccine 12.8.1.2. Adenovirus Oral Vaccine (Military) 12.8.1.3. Oral Polio Vaccine (OPV) 12.8.1.4. Yellow Fever Vaccine 12.8.1.5. Vaccinia (Smallpox) Vaccine 12.8.1.6. Other Viral Vaccines 12.8.2. Bacterial Vaccine 12.8.2.1. BCG (Tuberculosis) Vaccine 12.8.2.2. Live Cholera Vaccine 12.8.2.3. Typhoid Oral Vaccine 12.9. North America Live Attenuated Vaccines Market Value Share Analysis, By End user 12.10. North America Live Attenuated Vaccines Market Forecast, By End user 12.10.1. Clinics 12.10.2. Research Institute 12.10.3. Diagnostic Centers 12.10.4. Hospitals 12.10.5. Other End User 12.11. North America Live Attenuated Vaccines Market Value Share Analysis, by Country 12.12. North America Live Attenuated Vaccines Market Forecast, by Country 12.12.1. U.S. 12.12.2. Canada 12.13. North America Live Attenuated Vaccines Market Analysis, by Country 12.14. U.S. Live Attenuated Vaccines Market Forecast, By Vaccine Development 12.14.1. Live Animals 12.14.2. Embryonated Eggs 12.14.3. Tissue Culture 12.15. U.S. Live Attenuated Vaccines Market Forecast, Route of Administration 12.15.1. Intramuscular (IM) 12.15.2. Subcutaneous (SC) 12.15.3. Oral 12.15.3.1. intradermal (ID), 12.15.3.2. transcutaneous (TC), 12.15.3.3. nasal route 12.15.4. Other Routes 12.16. U.S. Live Attenuated Vaccines Market Forecast, By Type 12.16.1. Viral Vaccine 12.16.1.1. Varicella (Chickenpox) Vaccine 12.16.1.2. Adenovirus Oral Vaccine (Military) 12.16.1.3. Oral Polio Vaccine (OPV) 12.16.1.4. Yellow Fever Vaccine 12.16.1.5. Vaccinia (Smallpox) Vaccine 12.16.1.6. Other Viral Vaccines 12.16.2. Bacterial Vaccine 12.16.2.1. BCG (Tuberculosis) Vaccine 12.16.2.2. Live Cholera Vaccine 12.16.2.3. Typhoid Oral Vaccine 12.17. U.S. Live Attenuated Vaccines Market Forecast, By End user 12.17.1. Clinics 12.17.2. Research Institute 12.17.3. Diagnostic Centers 12.17.4. Hospitals 12.17.5. Other End User 12.18. Canada Live Attenuated Vaccines Market Forecast, By Vaccine Development 12.18.1. Live Animals 12.18.2. Embryonated Eggs 12.18.3. Tissue Culture 12.19. Canada Live Attenuated Vaccines Market Forecast, Route of Administration 12.19.1. Intramuscular (IM) 12.19.2. Subcutaneous (SC) 12.19.3. Oral 12.19.3.1. intradermal (ID), 12.19.3.2. transcutaneous (TC), 12.19.3.3. nasal route 12.19.4. Other Routes 12.20. Canada Live Attenuated Vaccines Market Forecast, By Type 12.20.1. Viral Vaccine 12.20.1.1. Varicella (Chickenpox) Vaccine 12.20.1.2. Adenovirus Oral Vaccine (Military) 12.20.1.3. Oral Polio Vaccine (OPV) 12.20.1.4. Yellow Fever Vaccine 12.20.1.5. Vaccinia (Smallpox) Vaccine 12.20.1.6. Other Viral Vaccines 12.20.2. Bacterial Vaccine 12.20.2.1. BCG (Tuberculosis) Vaccine 12.20.2.2. Live Cholera Vaccine 12.20.2.3. Typhoid Oral Vaccine 12.21. Canada Live Attenuated Vaccines Market Forecast, By End user 12.21.1. Clinics 12.21.2. Research Institute 12.21.3. Diagnostic Centers 12.21.4. Hospitals 12.21.5. Other End User 12.22. North America Live Attenuated Vaccines Market Attractiveness Analysis 12.22.1. By Vaccine Development 12.22.2. By Route of Administration 12.22.3. By Type 12.22.4. By End user 12.23. PEST Analysis 12.24. Key Trends 12.25. Key Developments 13. Europe Live Attenuated Vaccines Market Analysis 13.1. Key Findings 13.2. Europe Live Attenuated Vaccines Market Overview 13.3. Europe Live Attenuated Vaccines Market Value Share Analysis, By Vaccine Development 13.4. Europe Live Attenuated Vaccines Market Forecast, By Vaccine Development 13.4.1. Live Animals 13.4.2. Embryonated Eggs 13.4.3. Tissue Culture 13.5. Europe Live Attenuated Vaccines Market Value Share Analysis, Route of Administration 13.6. Europe Live Attenuated Vaccines Market Forecast, Route of Administration 13.6.1. Intramuscular (IM) 13.6.2. Subcutaneous (SC) 13.6.3. Oral 13.6.3.1. intradermal (ID), 13.6.3.2. transcutaneous (TC), 13.6.3.3. nasal route 13.6.4. Other Routes 13.7. Europe Live Attenuated Vaccines Market Value Share Analysis, By Type 13.8. Europe Live Attenuated Vaccines Market Forecast, By Type 13.8.1. Viral Vaccine 13.8.1.1. Varicella (Chickenpox) Vaccine 13.8.1.2. Adenovirus Oral Vaccine (Military) 13.8.1.3. Oral Polio Vaccine (OPV) 13.8.1.4. Yellow Fever Vaccine 13.8.1.5. Vaccinia (Smallpox) Vaccine 13.8.1.6. Other Viral Vaccines 13.8.2. Bacterial Vaccine 13.8.2.1. BCG (Tuberculosis) Vaccine 13.8.2.2. Live Cholera Vaccine 13.8.2.3. Typhoid Oral Vaccine 13.9. Europe Live Attenuated Vaccines Market Value Share Analysis, By End user 13.10. Europe Live Attenuated Vaccines Market Forecast, By End user 13.10.1. Clinics 13.10.2. Research Institute 13.10.3. Diagnostic Centers 13.10.4. Hospitals 13.10.5. Other End User 13.11. Europe Live Attenuated Vaccines Market Value Share Analysis, by Country 13.12. Europe Live Attenuated Vaccines Market Forecast, by Country 13.12.1. Germany 13.12.2. U.K. 13.12.3. France 13.12.4. Italy 13.12.5. Spain 13.12.6. Rest of Europe 13.13. Europe Live Attenuated Vaccines Market Analysis, by Country 13.14. Germany Live Attenuated Vaccines Market Forecast, By Vaccine Development 13.14.1. Live Animals 13.14.2. Embryonated Eggs 13.14.3. Tissue Culture 13.15. Germany Live Attenuated Vaccines Market Forecast, Route of Administration 13.15.1. Intramuscular (IM) 13.15.2. Subcutaneous (SC) 13.15.3. Oral 13.15.3.1. intradermal (ID), 13.15.3.2. transcutaneous (TC), 13.15.3.3. nasal route 13.15.4. Other Routes 13.16. Germany Live Attenuated Vaccines Market Forecast, By Type 13.16.1. Viral Vaccine 13.16.1.1. Varicella (Chickenpox) Vaccine 13.16.1.2. Adenovirus Oral Vaccine (Military) 13.16.1.3. Oral Polio Vaccine (OPV) 13.16.1.4. Yellow Fever Vaccine 13.16.1.5. Vaccinia (Smallpox) Vaccine 13.16.1.6. Other Viral Vaccines 13.16.2. Bacterial Vaccine 13.16.2.1. BCG (Tuberculosis) Vaccine 13.16.2.2. Live Cholera Vaccine 13.16.2.3. Typhoid Oral Vaccine 13.17. Germany Live Attenuated Vaccines Market Forecast, By End user 13.17.1. Clinics 13.17.2. Research Institute 13.17.3. Diagnostic Centers 13.17.4. Hospitals 13.17.5. Other End User 13.18. U.K. Live Attenuated Vaccines Market Forecast, By Vaccine Development 13.18.1. Live Animals 13.18.2. Embryonated Eggs 13.18.3. Tissue Culture 13.19. U.K. Live Attenuated Vaccines Market Forecast, Route of Administration 13.19.1. Intramuscular (IM) 13.19.2. Subcutaneous (SC) 13.19.3. Oral 13.19.3.1. intradermal (ID), 13.19.3.2. transcutaneous (TC), 13.19.3.3. nasal route 13.19.4. Other Routes 13.20. U.K. Live Attenuated Vaccines Market Forecast, By Type 13.20.1. Viral Vaccine 13.20.1.1. Varicella (Chickenpox) Vaccine 13.20.1.2. Adenovirus Oral Vaccine (Military) 13.20.1.3. Oral Polio Vaccine (OPV) 13.20.1.4. Yellow Fever Vaccine 13.20.1.5. Vaccinia (Smallpox) Vaccine 13.20.1.6. Other Viral Vaccines 13.20.2. Bacterial Vaccine 13.20.2.1. BCG (Tuberculosis) Vaccine 13.20.2.2. Live Cholera Vaccine 13.20.2.3. Typhoid Oral Vaccine 13.21. U.K. Live Attenuated Vaccines Market Forecast, By End user 13.21.1. Clinics 13.21.2. Research Institute 13.21.3. Diagnostic Centers 13.21.4. Hospitals 13.21.5. Other End User 13.22. France Live Attenuated Vaccines Market Forecast, By Vaccine Development 13.22.1. Live Animals 13.22.2. Embryonated Eggs 13.22.3. Tissue Culture 13.23. France Live Attenuated Vaccines Market Forecast, Route of Administration 13.23.1. Intramuscular (IM) 13.23.2. Subcutaneous (SC) 13.23.3. Oral 13.23.3.1. intradermal (ID), 13.23.3.2. transcutaneous (TC), 13.23.3.3. nasal route 13.23.4. Other Routes 13.24. France Live Attenuated Vaccines Market Forecast, By Type 13.24.1. Viral Vaccine 13.24.1.1. Varicella (Chickenpox) Vaccine 13.24.1.2. Adenovirus Oral Vaccine (Military) 13.24.1.3. Oral Polio Vaccine (OPV) 13.24.1.4. Yellow Fever Vaccine 13.24.1.5. Vaccinia (Smallpox) Vaccine 13.24.1.6. Other Viral Vaccines 13.24.2. Bacterial Vaccine 13.24.2.1. BCG (Tuberculosis) Vaccine 13.24.2.2. Live Cholera Vaccine 13.24.2.3. Typhoid Oral Vaccine 13.25. France Live Attenuated Vaccines Market Forecast, By End user 13.25.1. Clinics 13.25.2. Research Institute 13.25.3. Diagnostic Centers 13.25.4. Hospitals 13.25.5. Other End User 13.26. Italy Live Attenuated Vaccines Market Forecast, By Vaccine Development 13.26.1. Live Animals 13.26.2. Embryonated Eggs 13.26.3. Tissue Culture 13.27. Italy Live Attenuated Vaccines Market Forecast, Route of Administration 13.27.1. Intramuscular (IM) 13.27.2. Subcutaneous (SC) 13.27.3. Oral 13.27.3.1. intradermal (ID), 13.27.3.2. transcutaneous (TC), 13.27.3.3. nasal route 13.27.4. Other Routes 13.28. Italy Live Attenuated Vaccines Market Forecast, By Type 13.28.1. Viral Vaccine 13.28.1.1. Varicella (Chickenpox) Vaccine 13.28.1.2. Adenovirus Oral Vaccine (Military) 13.28.1.3. Oral Polio Vaccine (OPV) 13.28.1.4. Yellow Fever Vaccine 13.28.1.5. Vaccinia (Smallpox) Vaccine 13.28.1.6. Other Viral Vaccines 13.28.2. Bacterial Vaccine 13.28.2.1. BCG (Tuberculosis) Vaccine 13.28.2.2. Live Cholera Vaccine 13.28.2.3. Typhoid Oral Vaccine 13.29. Italy Live Attenuated Vaccines Market Forecast, By End user 13.29.1. Clinics 13.29.2. Research Institute 13.29.3. Diagnostic Centers 13.29.4. Hospitals 13.29.5. Other End User 13.30. Spain Live Attenuated Vaccines Market Forecast, By Vaccine Development 13.30.1. Live Animals 13.30.2. Embryonated Eggs 13.30.3. Tissue Culture 13.31. Spain Live Attenuated Vaccines Market Forecast, Route of Administration 13.31.1. Intramuscular (IM) 13.31.2. Subcutaneous (SC) 13.31.3. Oral 13.31.3.1. intradermal (ID), 13.31.3.2. transcutaneous (TC), 13.31.3.3. nasal route 13.31.4. Other Routes 13.32. Spain Live Attenuated Vaccines Market Forecast, By Type 13.32.1. Viral Vaccine 13.32.1.1. Varicella (Chickenpox) Vaccine 13.32.1.2. Adenovirus Oral Vaccine (Military) 13.32.1.3. Oral Polio Vaccine (OPV) 13.32.1.4. Yellow Fever Vaccine 13.32.1.5. Vaccinia (Smallpox) Vaccine 13.32.1.6. Other Viral Vaccines 13.32.2. Bacterial Vaccine 13.32.2.1. BCG (Tuberculosis) Vaccine 13.32.2.2. Live Cholera Vaccine 13.32.2.3. Typhoid Oral Vaccine 13.33. Spain Live Attenuated Vaccines Market Forecast, By End user 13.33.1. Clinics 13.33.2. Research Institute 13.33.3. Diagnostic Centers 13.33.4. Hospitals 13.33.5. Other End User 13.34. Rest of Europe Live Attenuated Vaccines Market Forecast, By Vaccine Development 13.34.1. Live Animals 13.34.2. Embryonated Eggs 13.34.3. Tissue Culture 13.35. Rest of Europe Live Attenuated Vaccines Market Forecast, Route of Administration 13.35.1. Intramuscular (IM) 13.35.2. Subcutaneous (SC) 13.35.3. Oral 13.35.3.1. intradermal (ID), 13.35.3.2. transcutaneous (TC), 13.35.3.3. nasal route 13.35.4. Other Routes 13.36. Rest of Europe Live Attenuated Vaccines Market Forecast, By Type 13.36.1. Viral Vaccine 13.36.1.1. Varicella (Chickenpox) Vaccine 13.36.1.2. Adenovirus Oral Vaccine (Military) 13.36.1.3. Oral Polio Vaccine (OPV) 13.36.1.4. Yellow Fever Vaccine 13.36.1.5. Vaccinia (Smallpox) Vaccine 13.36.1.6. Other Viral Vaccines 13.36.2. Bacterial Vaccine 13.36.2.1. BCG (Tuberculosis) Vaccine 13.36.2.2. Live Cholera Vaccine 13.36.2.3. Typhoid Oral Vaccine 13.37. Rest Of Europe Live Attenuated Vaccines Market Forecast, By End user 13.37.1. Clinics 13.37.2. Research Institute 13.37.3. Diagnostic Centers 13.37.4. Hospitals 13.37.5. Other End User 13.38. Europe Live Attenuated Vaccines Market Attractiveness Analysis 13.38.1. By Vaccine Development 13.38.2. Route of Administration 13.38.3. By Type 13.38.4. By End user 13.39. PEST Analysis 13.40. Key Trends 13.41. Key Developments 14. Asia Pacific Live Attenuated Vaccines Market Analysis 14.1. Key Findings 14.2. Asia Pacific Live Attenuated Vaccines Market Overview 14.3. Asia Pacific Live Attenuated Vaccines Market Value Share Analysis, By Vaccine Development 14.4. Asia Pacific Live Attenuated Vaccines Market Forecast, By Vaccine Development 14.4.1. Live Animals 14.4.2. Embryonated Eggs 14.4.3. Tissue Culture 14.5. Asia Pacific Live Attenuated Vaccines Market Value Share Analysis, Route of Administration 14.6. Asia Pacific Live Attenuated Vaccines Market Forecast, Route of Administration 14.6.1. Intramuscular (IM) 14.6.2. Subcutaneous (SC) 14.6.3. Oral 14.6.3.1. intradermal (ID), 14.6.3.2. transcutaneous (TC), 14.6.3.3. nasal route 14.6.4. Other Routes 14.7. Asia Pacific Live Attenuated Vaccines Market Value Share Analysis, By Type 14.8. Asia Pacific Live Attenuated Vaccines Market Forecast, By Type 14.8.1. Viral Vaccine 14.8.1.1. Varicella (Chickenpox) Vaccine 14.8.1.2. Adenovirus Oral Vaccine (Military) 14.8.1.3. Oral Polio Vaccine (OPV) 14.8.1.4. Yellow Fever Vaccine 14.8.1.5. Vaccinia (Smallpox) Vaccine 14.8.1.6. Other Viral Vaccines 14.8.2. Bacterial Vaccine 14.8.2.1. BCG (Tuberculosis) Vaccine 14.8.2.2. Live Cholera Vaccine 14.8.2.3. Typhoid Oral Vaccine 14.9. Asia Pacific Live Attenuated Vaccines Market Value Share Analysis, By End user 14.10. Asia Pacific Live Attenuated Vaccines Market Forecast, By End user 14.10.1. Clinics 14.10.2. Research Institute 14.10.3. Diagnostic Centers 14.10.4. Hospitals 14.10.5. Other End User 14.11. Asia Pacific Live Attenuated Vaccines Market Value Share Analysis, by Country 14.12. Asia Pacific Live Attenuated Vaccines Market Forecast, by Country 14.12.1. China 14.12.2. India 14.12.3. Japan 14.12.4. ASEAN 14.12.5. Rest of Asia Pacific 14.13. Asia Pacific Live Attenuated Vaccines Market Analysis, by Country 14.14. China Live Attenuated Vaccines Market Forecast, By Vaccine Development 14.14.1. Live Animals 14.14.2. Embryonated Eggs 14.14.3. Tissue Culture 14.15. China Live Attenuated Vaccines Market Forecast, Route of Administration 14.15.1. Intramuscular (IM) 14.15.2. Subcutaneous (SC) 14.15.3. Oral 14.15.3.1. intradermal (ID), 14.15.3.2. transcutaneous (TC), 14.15.3.3. nasal route 14.15.4. Other Routes 14.16. China Live Attenuated Vaccines Market Forecast, By Type 14.16.1. Viral Vaccine 14.16.1.1. Varicella (Chickenpox) Vaccine 14.16.1.2. Adenovirus Oral Vaccine (Military) 14.16.1.3. Oral Polio Vaccine (OPV) 14.16.1.4. Yellow Fever Vaccine 14.16.1.5. Vaccinia (Smallpox) Vaccine 14.16.1.6. Other Viral Vaccines 14.16.2. Bacterial Vaccine 14.16.2.1. BCG (Tuberculosis) Vaccine 14.16.2.2. Live Cholera Vaccine 14.16.2.3. Typhoid Oral Vaccine 14.17. China Live Attenuated Vaccines Market Forecast, By End user 14.17.1. Clinics 14.17.2. Research Institute 14.17.3. Diagnostic Centers 14.17.4. Hospitals 14.17.5. Other End User 14.18. India Live Attenuated Vaccines Market Forecast, By Vaccine Development 14.18.1. Live Animals 14.18.2. Embryonated Eggs 14.18.3. Tissue Culture 14.19. India Live Attenuated Vaccines Market Forecast, Route of Administration 14.19.1. Intramuscular (IM) 14.19.2. Subcutaneous (SC) 14.19.3. Oral 14.19.3.1. intradermal (ID), 14.19.3.2. transcutaneous (TC), 14.19.3.3. nasal route 14.19.4. Other Routes 14.20. India Live Attenuated Vaccines Market Forecast, By Type 14.20.1. Viral Vaccine 14.20.1.1. Varicella (Chickenpox) Vaccine 14.20.1.2. Adenovirus Oral Vaccine (Military) 14.20.1.3. Oral Polio Vaccine (OPV) 14.20.1.4. Yellow Fever Vaccine 14.20.1.5. Vaccinia (Smallpox) Vaccine 14.20.1.6. Other Viral Vaccines 14.20.2. Bacterial Vaccine 14.20.2.1. BCG (Tuberculosis) Vaccine 14.20.2.2. Live Cholera Vaccine 14.20.2.3. Typhoid Oral Vaccine 14.21. India Live Attenuated Vaccines Market Forecast, By End user 14.21.1. Clinics 14.21.2. Research Institute 14.21.3. Diagnostic Centers 14.21.4. Hospitals 14.21.5. Other End User 14.22. Japan Live Attenuated Vaccines Market Forecast, By Vaccine Development 14.22.1. Live Animals 14.22.2. Embryonated Eggs 14.22.3. Tissue Culture 14.23. Japan Live Attenuated Vaccines Market Forecast, Route of Administration 14.23.1. Intramuscular (IM) 14.23.2. Subcutaneous (SC) 14.23.3. Oral 14.23.3.1. intradermal (ID), 14.23.3.2. transcutaneous (TC), 14.23.3.3. nasal route 14.23.4. Other Routes 14.24. Japan Live Attenuated Vaccines Market Forecast, By Type 14.24.1. Viral Vaccine 14.24.1.1. Varicella (Chickenpox) Vaccine 14.24.1.2. Adenovirus Oral Vaccine (Military) 14.24.1.3. Oral Polio Vaccine (OPV) 14.24.1.4. Yellow Fever Vaccine 14.24.1.5. Vaccinia (Smallpox) Vaccine 14.24.1.6. Other Viral Vaccines 14.24.2. Bacterial Vaccine 14.24.2.1. BCG (Tuberculosis) Vaccine 14.24.2.2. Live Cholera Vaccine 14.24.2.3. Typhoid Oral Vaccine 14.25. Japan Live Attenuated Vaccines Market Forecast, By End user 14.25.1. Clinics 14.25.2. Research Institute 14.25.3. Diagnostic Centers 14.25.4. Hospitals 14.25.5. Other End User 14.26. ASEAN Live Attenuated Vaccines Market Forecast, By Vaccine Development 14.26.1. Live Animals 14.26.2. Embryonated Eggs 14.26.3. Tissue Culture 14.27. ASEAN Live Attenuated Vaccines Market Forecast, Route of Administration 14.27.1. Intramuscular (IM) 14.27.2. Subcutaneous (SC) 14.27.3. Oral 14.27.3.1. intradermal (ID), 14.27.3.2. transcutaneous (TC), 14.27.3.3. nasal route 14.27.4. Other Routes 14.28. ASEAN Live Attenuated Vaccines Market Forecast, By Type 14.28.1. Viral Vaccine 14.28.1.1. Varicella (Chickenpox) Vaccine 14.28.1.2. Adenovirus Oral Vaccine (Military) 14.28.1.3. Oral Polio Vaccine (OPV) 14.28.1.4. Yellow Fever Vaccine 14.28.1.5. Vaccinia (Smallpox) Vaccine 14.28.1.6. Other Viral Vaccines 14.28.2. Bacterial Vaccine 14.28.2.1. BCG (Tuberculosis) Vaccine 14.28.2.2. Live Cholera Vaccine 14.28.2.3. Typhoid Oral Vaccine 14.29. ASEAN Live Attenuated Vaccines Market Forecast, By End user 14.29.1. Clinics 14.29.2. Research Institute 14.29.3. Diagnostic Centers 14.29.4. Hospitals 14.29.5. Other End User 14.30. Rest of Asia Pacific Live Attenuated Vaccines Market Forecast, By Vaccine Development 14.30.1. Live Animals 14.30.2. Embryonated Eggs 14.30.3. Tissue Culture 14.31. Rest of Asia Pacific Live Attenuated Vaccines Market Forecast, Route of Administration 14.31.1. Intramuscular (IM) 14.31.2. Subcutaneous (SC) 14.31.3. Oral 14.31.3.1. intradermal (ID), 14.31.3.2. transcutaneous (TC), 14.31.3.3. nasal route 14.31.4. Other Routes 14.32. Rest of Asia Pacific Live Attenuated Vaccines Market Forecast, By Type 14.32.1. Viral Vaccine 14.32.1.1. Varicella (Chickenpox) Vaccine 14.32.1.2. Adenovirus Oral Vaccine (Military) 14.32.1.3. Oral Polio Vaccine (OPV) 14.32.1.4. Yellow Fever Vaccine 14.32.1.5. Vaccinia (Smallpox) Vaccine 14.32.1.6. Other Viral Vaccines 14.32.2. Bacterial Vaccine 14.32.2.1. BCG (Tuberculosis) Vaccine 14.32.2.2. Live Cholera Vaccine 14.32.2.3. Typhoid Oral Vaccine 14.33. Rest of Asia Pacific Live Attenuated Vaccines Market Forecast, By End user 14.33.1. Clinics 14.33.2. Research Institute 14.33.3. Diagnostic Centers 14.33.4. Hospitals 14.33.5. Other End User 14.34. Asia Pacific Live Attenuated Vaccines Market Attractiveness Analysis 14.34.1. By Vaccine Development 14.34.2. Route of Administration 14.34.3. By Type 14.34.4. By End user 14.35. PEST Analysis 14.36. Key Trends 14.37. Key Developments 15. Middle East & Africa Live Attenuated Vaccines Market Analysis 15.1. Key Findings 15.2. Middle East & Africa Live Attenuated Vaccines Market Overview 15.3. Middle East & Africa Live Attenuated Vaccines Market Value Share Analysis, By Vaccine Development 15.4. Middle East & Africa Live Attenuated Vaccines Market Forecast, By Vaccine Development 15.4.1. Live Animals 15.4.2. Embryonated Eggs 15.4.3. Tissue Culture 15.5. Middle East & Africa Live Attenuated Vaccines Market Value Share Analysis, Route of Administration 15.6. Middle East & Africa Live Attenuated Vaccines Market Forecast, Route of Administration 15.6.1. Intramuscular (IM) 15.6.2. Subcutaneous (SC) 15.6.3. Oral 15.6.3.1. intradermal (ID), 15.6.3.2. transcutaneous (TC), 15.6.3.3. nasal route 15.6.4. Other Routes 15.7. Middle East & Africa Live Attenuated Vaccines Market Value Share Analysis, By Type 15.8. Middle East & Africa Live Attenuated Vaccines Market Forecast, By Type 15.8.1. Viral Vaccine 15.8.1.1. Varicella (Chickenpox) Vaccine 15.8.1.2. Adenovirus Oral Vaccine (Military) 15.8.1.3. Oral Polio Vaccine (OPV) 15.8.1.4. Yellow Fever Vaccine 15.8.1.5. Vaccinia (Smallpox) Vaccine 15.8.1.6. Other Viral Vaccines 15.8.2. Bacterial Vaccine 15.8.2.1. BCG (Tuberculosis) Vaccine 15.8.2.2. Live Cholera Vaccine 15.8.2.3. Typhoid Oral Vaccine 15.9. Middle East & Africa Live Attenuated Vaccines Market Value Share Analysis, By End user 15.10. Middle East & Africa Live Attenuated Vaccines Market Forecast, By End user 15.10.1. Clinics 15.10.2. Research Institute 15.10.3. Diagnostic Centers 15.10.4. Hospitals 15.10.5. Other End User 15.11. Middle East & Africa Live Attenuated Vaccines Market Value Share Analysis, by Country 15.12. Middle East & Africa Live Attenuated Vaccines Market Forecast, by Country 15.12.1. GCC 15.12.2. South Africa 15.12.3. Rest of Middle East & Africa 15.13. Middle East & Africa Live Attenuated Vaccines Market Analysis, by Country 15.14. GCC Live Attenuated Vaccines Market Forecast, By Vaccine Development 15.14.1. Live Animals 15.14.2. Embryonated Eggs 15.14.3. Tissue Culture 15.15. GCC Live Attenuated Vaccines Market Forecast, Route of Administration 15.15.1. Intramuscular (IM) 15.15.2. Subcutaneous (SC) 15.15.3. Oral 15.15.3.1. intradermal (ID), 15.15.3.2. transcutaneous (TC), 15.15.3.3. nasal route 15.15.4. Other Routes 15.16. GCC Live Attenuated Vaccines Market Forecast, By Type 15.16.1. Viral Vaccine 15.16.1.1. Varicella (Chickenpox) Vaccine 15.16.1.2. Adenovirus Oral Vaccine (Military) 15.16.1.3. Oral Polio Vaccine (OPV) 15.16.1.4. Yellow Fever Vaccine 15.16.1.5. Vaccinia (Smallpox) Vaccine 15.16.1.6. Other Viral Vaccines 15.16.2. Bacterial Vaccine 15.16.2.1. BCG (Tuberculosis) Vaccine 15.16.2.2. Live Cholera Vaccine 15.16.2.3. Typhoid Oral Vaccine 15.17. GCC Live Attenuated Vaccines Market Forecast, By End user 15.17.1. Clinics 15.17.2. Research Institute 15.17.3. Diagnostic Centers 15.17.4. Hospitals 15.17.5. Other End User 15.18. South Africa Live Attenuated Vaccines Market Forecast, By Vaccine Development 15.18.1. Live Animals 15.18.2. Embryonated Eggs 15.18.3. Tissue Culture 15.19. South Africa Live Attenuated Vaccines Market Forecast, Route of Administration 15.19.1. Intramuscular (IM) 15.19.2. Subcutaneous (SC) 15.19.3. Oral 15.19.3.1. intradermal (ID), 15.19.3.2. transcutaneous (TC), 15.19.3.3. nasal route 15.19.4. Other Routes 15.20. South Africa Live Attenuated Vaccines Market Forecast, By Type 15.20.1. Viral Vaccine 15.20.1.1. Varicella (Chickenpox) Vaccine 15.20.1.2. Adenovirus Oral Vaccine (Military) 15.20.1.3. Oral Polio Vaccine (OPV) 15.20.1.4. Yellow Fever Vaccine 15.20.1.5. Vaccinia (Smallpox) Vaccine 15.20.1.6. Other Viral Vaccines 15.20.2. Bacterial Vaccine 15.20.2.1. BCG (Tuberculosis) Vaccine 15.20.2.2. Live Cholera Vaccine 15.20.2.3. Typhoid Oral Vaccine 15.21. South Africa Live Attenuated Vaccines Market Forecast, By End user 15.21.1. Clinics 15.21.2. Research Institute 15.21.3. Diagnostic Centers 15.21.4. Hospitals 15.21.5. Other End User 15.22. Rest of Middle East & Africa Live Attenuated Vaccines Market Forecast, By Vaccine Development 15.22.1. Live Animals 15.22.2. Embryonated Eggs 15.22.3. Tissue Culture 15.23. Rest of Middle East & Africa Live Attenuated Vaccines Market Forecast, Route of Administration 15.23.1. Intramuscular (IM) 15.23.2. Subcutaneous (SC) 15.23.3. Oral 15.23.3.1. intradermal (ID), 15.23.3.2. transcutaneous (TC), 15.23.3.3. nasal route 15.23.4. Other Routes 15.24. Rest of Middle East & Africa Live Attenuated Vaccines Market Forecast, By Type 15.24.1. Viral Vaccine 15.24.1.1. Varicella (Chickenpox) Vaccine 15.24.1.2. Adenovirus Oral Vaccine (Military) 15.24.1.3. Oral Polio Vaccine (OPV) 15.24.1.4. Yellow Fever Vaccine 15.24.1.5. Vaccinia (Smallpox) Vaccine 15.24.1.6. Other Viral Vaccines 15.24.2. Bacterial Vaccine 15.24.2.1. BCG (Tuberculosis) Vaccine 15.24.2.2. Live Cholera Vaccine 15.24.2.3. Typhoid Oral Vaccine 15.25. Rest of Middle East & Africa Live Attenuated Vaccines Market Forecast, By End user 15.25.1. Clinics 15.25.2. Research Institute 15.25.3. Diagnostic Centers 15.25.4. Hospitals 15.25.5. Other End User 15.26. Middle East & Africa Live Attenuated Vaccines Market Attractiveness Analysis 15.26.1. By Vaccine Development 15.26.2. Route of Administration 15.26.3. By Type 15.26.4. By End user 15.27. PEST Analysis 15.28. Key Trends 15.29. Key Developments 16. South America Live Attenuated Vaccines Market Analysis 16.1. Key Findings 16.2. South America Live Attenuated Vaccines Market Overview 16.3. South America Live Attenuated Vaccines Market Value Share Analysis, By Vaccine Development 16.4. South America Live Attenuated Vaccines Market Forecast, By Vaccine Development 16.4.1. Live Animals 16.4.2. Embryonated Eggs 16.4.3. Tissue Culture 16.5. South America Live Attenuated Vaccines Market Value Share Analysis, Route of Administration 16.6. South America Live Attenuated Vaccines Market Forecast, Route of Administration 16.6.1. Intramuscular (IM) 16.6.2. Subcutaneous (SC) 16.6.3. Oral 16.6.3.1. intradermal (ID), 16.6.3.2. transcutaneous (TC), 16.6.3.3. nasal route 16.6.4. Other Routes 16.7. South America Live Attenuated Vaccines Market Value Share Analysis, By Type 16.8. South America Live Attenuated Vaccines Market Forecast, By Type 16.8.1. Viral Vaccine 16.8.1.1. Varicella (Chickenpox) Vaccine 16.8.1.2. Adenovirus Oral Vaccine (Military) 16.8.1.3. Oral Polio Vaccine (OPV) 16.8.1.4. Yellow Fever Vaccine 16.8.1.5. Vaccinia (Smallpox) Vaccine 16.8.1.6. Other Viral Vaccines 16.8.2. Bacterial Vaccine 16.8.2.1. BCG (Tuberculosis) Vaccine 16.8.2.2. Live Cholera Vaccine 16.8.2.3. Typhoid Oral Vaccine 16.9. South America Live Attenuated Vaccines Market Value Share Analysis, By End user 16.10. South America Live Attenuated Vaccines Market Forecast, By End user 16.10.1. Clinics 16.10.2. Research Institute 16.10.3. Diagnostic Centers 16.10.4. Hospitals 16.10.5. Other End User 16.11. South America Live Attenuated Vaccines Market Value Share Analysis, by Country 16.12. South America Live Attenuated Vaccines Market Forecast, by Country 16.12.1. Brazil 16.12.2. Mexico 16.12.3. Rest of South America 16.13. South America Live Attenuated Vaccines Market Analysis, by Country 16.14. Brazil Live Attenuated Vaccines Market Forecast, By Vaccine Development 16.14.1. Live Animals 16.14.2. Embryonated Eggs 16.14.3. Tissue Culture 16.15. Brazil Live Attenuated Vaccines Market Forecast, Route of Administration 16.15.1. Intramuscular (IM) 16.15.2. Subcutaneous (SC) 16.15.3. Oral 16.15.3.1. intradermal (ID), 16.15.3.2. transcutaneous (TC), 16.15.3.3. nasal route 16.15.4. Other Routes 16.16. Brazil Live Attenuated Vaccines Market Forecast, By Type 16.16.1. Viral Vaccine 16.16.1.1. Varicella (Chickenpox) Vaccine 16.16.1.2. Adenovirus Oral Vaccine (Military) 16.16.1.3. Oral Polio Vaccine (OPV) 16.16.1.4. Yellow Fever Vaccine 16.16.1.5. Vaccinia (Smallpox) Vaccine 16.16.1.6. Other Viral Vaccines 16.16.2. Bacterial Vaccine 16.16.2.1. BCG (Tuberculosis) Vaccine 16.16.2.2. Live Cholera Vaccine 16.16.2.3. Typhoid Oral Vaccine 16.17. Brazil Live Attenuated Vaccines Market Forecast, By End user 16.17.1. Clinics 16.17.2. Research Institute 16.17.3. Diagnostic Centers 16.17.4. Hospitals 16.17.5. Other End User 16.18. Mexico Live Attenuated Vaccines Market Forecast, By Vaccine Development 16.18.1. Live Animals 16.18.2. Embryonated Eggs 16.18.3. Tissue Culture 16.19. Mexico Live Attenuated Vaccines Market Forecast, Route of Administration 16.19.1. Intramuscular (IM) 16.19.2. Subcutaneous (SC) 16.19.3. Oral 16.19.3.1. intradermal (ID), 16.19.3.2. transcutaneous (TC), 16.19.3.3. nasal route 16.19.4. Other Routes 16.20. Mexico Live Attenuated Vaccines Market Forecast, By Type 16.20.1. Viral Vaccine 16.20.1.1. Varicella (Chickenpox) Vaccine 16.20.1.2. Adenovirus Oral Vaccine (Military) 16.20.1.3. Oral Polio Vaccine (OPV) 16.20.1.4. Yellow Fever Vaccine 16.20.1.5. Vaccinia (Smallpox) Vaccine 16.20.1.6. Other Viral Vaccines 16.20.2. Bacterial Vaccine 16.20.2.1. BCG (Tuberculosis) Vaccine 16.20.2.2. Live Cholera Vaccine 16.20.2.3. Typhoid Oral Vaccine 16.21. Mexico Live Attenuated Vaccines Market Forecast, By End user 16.21.1. Clinics 16.21.2. Research Institute 16.21.3. Diagnostic Centers 16.21.4. Hospitals 16.21.5. Other End User 16.22. Rest of South America Live Attenuated Vaccines Market Forecast, By Vaccine Development 16.22.1. Live Animals 16.22.2. Embryonated Eggs 16.22.3. Tissue Culture 16.23. Rest of South America Live Attenuated Vaccines Market Forecast, Route of Administration 16.23.1. Intramuscular (IM) 16.23.2. Subcutaneous (SC) 16.23.3. Oral 16.23.3.1. intradermal (ID), 16.23.3.2. transcutaneous (TC), 16.23.3.3. nasal route 16.23.4. Other Routes 16.24. Rest of South America Live Attenuated Vaccines Market Forecast, By Type 16.24.1. Viral Vaccine 16.24.1.1. Varicella (Chickenpox) Vaccine 16.24.1.2. Adenovirus Oral Vaccine (Military) 16.24.1.3. Oral Polio Vaccine (OPV) 16.24.1.4. Yellow Fever Vaccine 16.24.1.5. Vaccinia (Smallpox) Vaccine 16.24.1.6. Other Viral Vaccines 16.24.2. Bacterial Vaccine 16.24.2.1. BCG (Tuberculosis) Vaccine 16.24.2.2. Live Cholera Vaccine 16.24.2.3. Typhoid Oral Vaccine 16.25. Rest of South America Live Attenuated Vaccines Market Forecast, By End user 16.25.1. Clinics 16.25.2. Research Institute 16.25.3. Diagnostic Centers 16.25.4. Hospitals 16.25.5. Other End User 16.26. South America Live Attenuated Vaccines Market Attractiveness Analysis 16.26.1. By Vaccine Development 16.26.2. Route of Administration 16.26.3. By Type 16.26.4. By End user 16.27. PEST Analysis 16.28. Key Trends 16.29. Key Developments 17. Company Profiles 17.1. Market Share Analysis, by Company 17.2. Competition Matrix 17.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 17.2.2. New Product Launches and Product Enhancements 17.2.3. Market Consolidation 17.2.3.1. M&A by Regions, Investment and Applications 17.2.3.2. M&A Key Players, Forward Integration and Backward Integration 17.1. Company Profiles: Key Players 17.1.1. Merck & Co., Inc. 17.1.1.1. Company Overview 17.1.1.2. Financial Overview 17.1.1.3. Product Portfolio 17.1.1.4. Business Strategy 17.1.1.5. Recent Developments 17.1.1.6. Development Footprint 17.1.2. GlaxoSmithKline plc 17.1.3. Pfizer Inc. 17.1.4. CSL Limited 17.1.5. MedImmune LLC 17.1.6. Sanofi 17.1.7. Astellas Pharma 17.1.8. Johnson and Johnson 17.1.9. Serum institute of India Pvt. Ltd. 17.1.10. Codagenix Inc. 17.1.11. BioDiem 17.1.12. AstraZeneca 17.1.13. Emergent BioSolutions Inc. 17.1.14. Vivaldi Biosciences Inc. 17.1.15. Daiichi Sankyo Co., Ltd. 17.1.16. Takeda Pharmaceutical Company Limited 17.1.17. NOVAVAX, INC. 17.1.18. Boehringer Ingelheim International GmbH 17.1.19. Sanaria 18. Primary Key Insights